Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Public and Community Engagement group at OUCRU has a strong commitment to community engagement, particularly in the field of vaccine research. Let’s look at some featured projects in all OUCRU’s local offices, spreading out from typhoid in Nepal to TB in Vietnam.

Child being vaccinated

Nepal: Tackling Typhoid 

Typhoid is a public health problem in Nepal. With its high incidence, Kathmandu, the capital city of Nepal, has been labelled the enteric fever capital of the world. To reduce the morbidity and mortality, the Typhoid Vaccine Acceleration Consortium (TyVAC) supported the introduction of typhoid conjugate vaccine (TCV) for Gavi eligible countries with a typhoid disease burden using a World Health Organization (WHO) prequalified vaccine. 

However, in Nepal, clinical research is often met with distrust and negative opinions. Therefore, when the TyVAC-Nepal study was conducted, a continuous public engagement strategy had been used to gain and maintain community trust.  

The strategy involved three tiers of engagement with various stakeholders, including parents/guardians of vaccinated children, before, during, and after vaccination.

Before vaccination, initial engagement involved Lalitpur Metropolitan City’s elected representatives. The second engagement level was carried out in all 17 municipal wards, attended by various local stakeholders, including ward chairpersons and elected members. The third level involved engaging with mothers’ groups and schools before vaccination, and subsequently with parents of vaccinated children and non-vaccinated community members. School engagement with students and teachers was also part of this third level.

Despite challenges such as misinformation, skepticism, and logistical issues, the study achieved its target of vaccinating 20,019 children. The study found that using community-friendly language, involving locals in the consent process, and adapting to community needs and expectations were crucial in overcoming hurdles and building trust.

Indonesia: Battling Malaria 

Over 150 million Indonesians are at risk of malaria from five Plasmodium species. Malaria is particularly severe in rural and impoverished areas. 

The Indonesian Army deployment of malaria-naïve (or minimally malaria-exposed) infantry soldiers to Papua are highly exposed and vulnerable to severe forms of clinical malaria. Therefore, they view the development of a vaccine as an ideal solution. They believe it could serve as a powerful tool for both the prevention of new cases and the eventual elimination of the disease within their ranks. 

The Indonesia trial is being performed as a collaboration between the Indonesian Army, the Eijkman Institute, the University of Indonesia School of Medicine, and OUCRU Indonesia (formerly EOCRU). 

This is the first time a malaria vaccine has been tested in a real-world setting outside Africa in many years. It’s also the first time the vaccines have been tested against natural strains of P. falciparum and P. vivax outside of Africa.

Vietnam: Working towards #EndTB Goal

Tuberculosis (TB) is a leading cause of death from infectious diseases and antimicrobial resistance, affecting about a quarter of the world’s population. The Global tuberculosis report 2018 estimated Viet Nam had 124.000 new TB cases and 12.000 TB-related deaths in 2017. Despite advances in diagnosis and treatment, TB still causes significant human suffering and economic burden. The current BCG vaccine, developed over 100 years ago, only offers partial protection and does not protect adults and adolescents, who are the majority of TB transmitters. Achieving the WHO’s End TB Strategy targets by 2035 will require a new vaccine effective across all age groups, and vaccines are the best chance to contain the spread of multi-drug resistant tuberculosis.

One of OUCRU’s initial steps towards new TB vaccine and other TB prevention approaches is consulting with the community through the Public and Community Engagement Group’s initiative, the Health Research Advisory Board. Through several meetings and discussions, researchers expect to have opportunities to understand the awareness, concerns, perspectives, and TB vaccine readiness of several communities represented in the board.


Visit the Public and Community Engagement pages on the OUCRU website

The full News is available on the OUCRU website